Research view
Switch to patient viewAcute myeloid leukaemia: trials that stopped early
Trials on Acute myeloid leukaemia that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
167 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.
Terminated
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
Reason given in the registry “The sponsor is no longer supporting the drug”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Dec 2024.
- Ended
- Jul 2024
- Phase
- Phase 2
- Run by
- Washington University School of Medicine
- Registry record
- NCT04582864
Withdrawn
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Reason given in the registry “Lack of funding”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Dec 2024.
- Ended
- Jun 2026
- Phase
- Phase 1
- Run by
- Leland Metheny
- Registry record
- NCT03939585
Terminated
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
Reason given in the registry “Lack of Enrollment”
Quoted unchanged from ClinicalTrials.gov; record updated 18 Nov 2024.
- Ended
- Dec 2023
- Phase
- Phase 1
- Run by
- Hackensack Meridian Health
- Registry record
- NCT02846376
Withdrawn
Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Reason given in the registry “Difficulty in joining the group”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Nov 2024.
- Ended
- Dec 2023
- Phase
- Phase 1
- Run by
- Beijing Boren Hospital
- Registry record
- NCT05266950
Withdrawn
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
Reason given in the registry “Could not accrue”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Oct 2024.
- Phase
- Phase 1/2
- Run by
- Guenther Koehne
- Registry record
- NCT04982354
Withdrawn
Tislelizumab with Azacitidine in the Treatment of R/R AML
Reason given in the registry “withdrawn”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.
- Ended
- Jun 2025
- Phase
- Phase 1/2
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
- Registry record
- NCT06586099
Terminated
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
Reason given in the registry “Sponsor decision”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.
- Ended
- Jul 2024
- Phase
- Phase 1/2
- Run by
- K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
- Registry record
- NCT05682170
Withdrawn
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
Reason given in the registry “Withdrawn -ctms”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.
- Ended
- Feb 2026
- Phase
- Phase 1
- Run by
- City of Hope Medical Center
- Registry record
- NCT05823480
Withdrawn
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Reason given in the registry “PI decided not to move forward with the study”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.
- Ended
- Sept 2025
- Phase
- Phase 2
- Run by
- Wake Forest University Health Sciences
- Registry record
- NCT05854966
Withdrawn
Antimicrobial Revision in Persistent Febrile Neutropenia
Reason given in the registry “Study was never initiated or activated - Reason was lack of funding”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.
- Ended
- Apr 2025
- Phase
- Phase 4
- Run by
- Wake Forest University Health Sciences
- Registry record
- NCT05784844
Terminated
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Reason given in the registry “A business decision was made by Pfizer to terminate the study. Termination was not due to any safety concerns, requests from regulatory authorities, changes to the benefit/risk profile or any new concerns regarding the investigational product.”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Sept 2024.
- Ended
- Jul 2024
- Phase
- Phase 1
- Run by
- Pfizer
- Registry record
- NCT03530683
Terminated
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
Reason given in the registry “On 7/26/24 the Sponsor-Investigator was notified GlycoMimetics was terminating contracting for NCT05569512 following company restructuring. This notification came ahead of the study meeting criteria to progress from Phase 1 to Phase 2.”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Aug 2024.
- Ended
- Dec 2023
- Phase
- Phase 1
- Run by
- Malika Kapadia
- Registry record
- NCT05569512
Withdrawn
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Reason given in the registry “Sponsor withdrew support.”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Aug 2024.
- Phase
- Phase 1
- Run by
- Medical College of Wisconsin
- Registry record
- NCT06007911
Terminated
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
Reason given in the registry “Sponsor decision”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Aug 2024.
- Ended
- Apr 2024
- Phase
- Phase 1/2
- Run by
- Kronos Bio
- Registry record
- NCT05028751
Withdrawn
ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML
Reason given in the registry “Lack of Funding - no safety issue with Drug; Company Permanently Closed”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Aug 2024.
- Ended
- Jun 2024
- Phase
- Phase 1
- Run by
- Elucida Oncology
- Registry record
- NCT05622591
Terminated
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
Reason given in the registry “Trial failed to meet primary endpoint.”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Jul 2024.
- Ended
- Mar 2024
- Phase
- Phase 3
- Run by
- GlycoMimetics Incorporated
- Registry record
- NCT03616470
Terminated
Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)
Reason given in the registry “Resources related issues”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Jul 2024.
- Ended
- May 2024
- Run by
- UNC Lineberger Comprehensive Cancer Center
- Registry record
- NCT04920188
Withdrawn
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant
Reason given in the registry “Unable to accommodate FDA recommendations for protocol revisions”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Jun 2024.
- Phase
- Phase 2
- Run by
- Northside Hospital, Inc.
- Registry record
- NCT06337331
Terminated
A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
Reason given in the registry “Business objectives have changed.”
Quoted unchanged from ClinicalTrials.gov; record updated 31 May 2024.
- Ended
- Apr 2024
- Phase
- Phase 1
- Run by
- Celgene
- Registry record
- NCT04336982
Withdrawn
Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML
Reason given in the registry “investigator's unavailability”
Quoted unchanged from ClinicalTrials.gov; record updated 23 May 2024.
- Ended
- Dec 2024
- Run by
- Centre Hospitalier Régional Metz-Thionville
- Registry record
- NCT05309018
Withdrawn
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Reason given in the registry “PI has left IU with no plan to initiate study at IU”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Apr 2024.
- Ended
- Dec 2025
- Phase
- Phase 1/2
- Run by
- Indiana University
- Registry record
- NCT05895201
Withdrawn
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review
Reason given in the registry “Strategic considerations”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Apr 2024.
- Ended
- Apr 2024
- Run by
- AbbVie
- Registry record
- NCT06362031
Withdrawn
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Reason given in the registry “waiting for update from Study Lead”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Apr 2024.
- Phase
- Phase 1/2
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT05367401
Withdrawn
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Reason given in the registry “trial was not opened”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Mar 2024.
- Ended
- Aug 2026
- Phase
- Phase 1
- Run by
- Jonsson Comprehensive Cancer Center
- Registry record
- NCT05720988
Terminated
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
Reason given in the registry “The study was terminated after conducting an interim analysis of the available data where it became evident that the observed efficacy results were not in alignment with the initially set expectations.”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Feb 2024.
- Ended
- Feb 2024
- Phase
- Phase 1
- Run by
- Hemavant Sciences GmbH
- Registry record
- NCT02841540
Terminated
Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Reason given in the registry “Discontinued”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Feb 2024.
- Ended
- Dec 2023
- Phase
- Phase 1/2
- Run by
- CicloMed LLC
- Registry record
- NCT04956042
Withdrawn
Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS
Reason given in the registry “Trial was stopped prematurely due to safety reasons”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Feb 2024.
- Phase
- Phase 2
- Run by
- Uwe Platzbecker
- Registry record
- NCT05829434
Terminated
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Reason given in the registry “Company Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 31 Jan 2024.
- Ended
- Jan 2024
- Phase
- Phase 1
- Run by
- Prelude Therapeutics Incorporated
- Registry record
- NCT05107856
Suspended
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
Reason given in the registry “Prioritization”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Jan 2024.
- Ended
- Apr 2024
- Phase
- Phase 1
- Run by
- Syros Pharmaceuticals
- Registry record
- NCT04996030
Withdrawn
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
Reason given in the registry “Lack of funding.”
Quoted unchanged from ClinicalTrials.gov; record updated 26 Dec 2023.
- Phase
- Phase 2
- Run by
- Yale University
- Registry record
- NCT06180863
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.